23rd Global Cardio Vascular Clinical Trialists (CVCT) Forum, 7-9 December 2026, Washington DC
Read more at this link
Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026
In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease
Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026
Could a new protein become a future treatment target in pulmonary arterial hypertension(PAH)? Researchers have identified a protein called placental growth factor (PlGF) as a possible new driver of pulmonary arterial hypertension (PAH). Although its name suggests it is only involved in pregnancy, placental growth factor is also active in blood vessels and the immune
Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026
Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard
Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026
This single-center retrospective study, conducted at Qilu Hospital, Shandong University (China), from February 2022 to November 2023, set out to compare two strategies for selexipag-based triple combination therapy in patients with pulmonary arterial hypertension (PAH): starting all three drugs together (initial/upfront triple therapy) versus adding selexipag on top of existing dual therapy (early sequential triple
Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026
French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked
New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension
New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up.
Lung Transplant Recipient Reaches Record High Altitude on Mount Aconcagua (6,961 m) during a scientific expedition, Transplant International, May 12, 2026
A 51-year-old lung transplant recipient — transplanted in 2002 for cystic fibrosis — successfully reached the summit of Mount Aconcagua in Argentina (6,961 m) in January 2026, without supplemental oxygen. This is the highest altitude ever recorded for a lung transplant recipient. The achievement was part of an international medical expedition organised by the Vienna
Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026
Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential control arms. The method has
CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30
One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical
Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026
A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and
A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026
The authors of a study recently published on CHEST retrospectively analyzed data from adult patients enrolled in the French Pulmotension registry (Commission Nationale de l’Informatique et des Libertés No. 842063) from the Limoges Competence Center between May 1, 2020, and May 1, 2021. Inclusion criteria were the following: (1) confirmed pulmonary hypertension (PH) diagnosed by
Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026
A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label
Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026
A large US claims-based study has shed light on a worrying trend: pulmonary arterial hypertension linked to methamphetamine use (Meth-APAH) is rising fast — up 93% between 2018 and 2022, a rate disproportionate to the general rise in methamphetamine use itself. Compared to other pulmonary arterial hypertension patients, those with Meth-APAH tend to be younger,
2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026
A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians
Comparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026
A retrospective study based on data from the Spanish pulmonary arterial hypertension Registry (REHAP) set out to compare the demographic and clinical profiles, comorbidity burden, and survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) against those with idiopathic pulmonary arterial hypertension (IPAH). The study, covering the period 2014–2023, included 757 patients
Ensuring cultural relevance in pulmonary arterial hypertension QOL questionnaire adaptation: the Thai emPHasis-10 case, Journal of Patient-Reported Outcomes, February 20, 2026
The emPHasis-10 questionnaire is a specialized tool for assessing health-related quality of life in pulmonary arterial hypertension patients. A comprehensive validation process was undertaken by researchers in Thailand including forward-backward translation, expert content validity assessment using Item-Objective Congruence (IOC) index by five specialists, and reliability testing with 20 Thai PAH patients using both internal consistency
Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026
Pulmonary Hypertension News published a report on February 2, 2026, about a case series and literature review found that ECMO (extracorporeal membrane oxygenation)—a life-support machine that temporarily replaces heart and lung function—significantly improves survival in pregnant women with severe pulmonary arterial hypertension (PAH). The study documented five cases where the machine was used as rescue
Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up, European Heart Journal, February 6, 2026
An Italian study examined whether echocardiographic patterns of right heart changes could improve risk prediction in pulmonary arterial hypertension patients beyond current tools. Researchers defined four phenotypes based on right ventricular size and function, then followed patients for nearly 4 years. They found that these echo-based classifications provided additional prognostic information independent of existing risk
Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026
A recent study published in Pulmonary Circulation, summarised in an article by Andrea Lob on Pulmonary Hypertension News, found that early diagnosis of pulmonary arterial hypertension (PAH) – within six months of first healthcare contact for symptoms – improves five-year survival by 42 percentage points compared to delayed diagnosis (two years or more). Five-year survival